{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:26Z","timestamp":1792839746415,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T00:00:00Z","timestamp":1703462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU 05.809"],"award-info":[{"award-number":["TTU 05.809"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jhepr.2023.100994","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T05:35:19Z","timestamp":1707284119000},"page":"100994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real-world effectiveness of voxilaprevir\/velpatasvir\/sofosbuvir in patients following DAA failure"],"prefix":"10.1016","volume":"6","author":[{"given":"Christiana","family":"Graf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-4669","authenticated-orcid":false,"given":"Elisabetta","family":"Degasperi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Paolucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Llaneras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Vermehren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Dultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Henrik","family":"Peiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-9910","authenticated-orcid":false,"given":"Fabian","family":"Finkelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-7476","authenticated-orcid":false,"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Sarrazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2023.100994_bib1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-med-052915-015720","article-title":"Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs","volume":"68","author":"Naggie","year":"2017","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jhepr.2023.100994_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(15)33722-7","article-title":"Tu1033 evaluation of access to care in patients prescribed sofosbuvir-containing regimens: data from the TRIO network","volume":"148","author":"Younossi","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100994_bib3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3851\/IMP3202","article-title":"Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3\/4A protease inhibitor","volume":"23","author":"Lawitz","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhepr.2023.100994_bib4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib5","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jhepr.2023.100994_bib6","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2023.100994_bib7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(18)30118-3","article-title":"Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1","volume":"3","author":"Bourli\u00e8re","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib8","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jhep.2018.07.023","article-title":"No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients","volume":"69","author":"Sarrazin","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jhep.2022.08.016","article-title":"Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure","volume":"78","author":"Dietz","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib10","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1128\/AAC.02494-12","article-title":"Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir","volume":"57","author":"Wang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jhepr.2023.100994_bib11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3851\/IMP3181","article-title":"Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir","volume":"23","author":"Wyles","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhepr.2023.100994_bib12","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2019.07.020","article-title":"Real-life effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients with previous DAA failure","volume":"71","author":"Degasperi","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jhep.2018.09.018","article-title":"Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir\/sofosbuvir in hepatitis C genotype 2 and 3","volume":"70","author":"Belperio","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib14","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs","volume":"71","author":"Llaneras","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib15","first-page":"841","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: results from the German Hepatitis C-Registry (DHC-R)","volume":"58","author":"Vermehren","year":"2020","journal-title":"Z\u00a0Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100994_bib16","doi-asserted-by":"crossref","first-page":"e3288","DOI":"10.1093\/cid\/ciaa1318","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir\/voxilaprevir for hepatitis C virus (HCV) NS5A-inhibitor experienced patients with difficult to cure characteristics","volume":"73","author":"Papaluca","year":"2021","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.jhepr.2023.100994_bib17","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/jvh.13549","article-title":"Real world SOF\/VEL\/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy","volume":"28","author":"Smith","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2023.100994_bib18","doi-asserted-by":"crossref","first-page":"S356","DOI":"10.1016\/S0168-8278(20)31209-5","article-title":"Real-world effectiveness of sofosbuvir\/velpatasvir\/voxilaprevir as a hepatitis C virus infection salvage treatment","volume":"73","author":"Janjua","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib19","doi-asserted-by":"crossref","first-page":"S846","DOI":"10.1016\/S0168-8278(20)32136-X","article-title":"Pangenotypic therapies glecaprevir-pibrentasvir (G-P) and sofosbuvir-velpatasvir-voxilaprevir (S-V-V) after failure with interferon (IFN)-free direct-acting antiviral (DAA) treatment for hepatitis C","volume":"73","author":"Flamm","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib20","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment failure with DAA therapy: importance of resistance","volume":"74","author":"Sarrazin","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib21","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib22","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jhep.2020.11.017","article-title":"Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy","volume":"74","author":"Dietz","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104694","article-title":"Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure","volume":"174","author":"Chen","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhepr.2023.100994_bib24","doi-asserted-by":"crossref","first-page":"019855","DOI":"10.1128\/JCM.01985-20","article-title":"Amino acid substitutions associated with treatment failure for hepatitis C virus infection","volume":"58","author":"Soria","year":"2020","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jhepr.2023.100994_bib25","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/jvh.13497","article-title":"Resistance-associated substitutions after sofosbuvir\/velpatasvir\/voxilaprevir triple therapy failure","volume":"28","author":"Garcia-Cehic","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2023.100994_bib26","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2017.11.007","article-title":"Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals","volume":"154","author":"Dietz","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100994_bib27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"Electronic address: easloffice@easloffice.eu. EASL Recommendations on Treatment of Hepatitis C 2016","volume":"66","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib28","doi-asserted-by":"crossref","first-page":"e799","DOI":"10.1093\/cid\/ciaa1510","article-title":"Salvage therapy with sofosbuvir\/velpatasvir\/voxilaprevir in DAA-experienced patients: results from a prospective Canadian Registry","volume":"72","author":"Onofrio","year":"2021","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.jhepr.2023.100994_bib29","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib30","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.14309\/ajg.0000000000000248","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir for previous treatment failures with glecaprevir\/pibrentasvir in chronic hepatitis C infection","volume":"114","author":"Pearlman","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100994_bib31","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/S0618-8278(19)30391-3","article-title":"THU-116-Effectiveness of the salvage therapy sofosbuvir-velpatasvir-voxilaprevir (SOF-VEL-VOX) in chronic hepatitis C: clinical practice experience from the TRIO Network","volume":"70","author":"Bacon","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib32","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/hep.29556","article-title":"OATP1B1 and DAA treatment for hepatitis C in patients with hepatocellular carcinoma","volume":"66","author":"Chtioui","year":"2017","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jhepr.2023.100994_bib33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/MOG.0000000000000431","article-title":"Direct-acting antiviral treatment for patients with hepatocellular carcinoma","volume":"34","author":"Kushner","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100994_bib34","first-page":"1986","article-title":"HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma","volume":"39","author":"Sorbo","year":"2019","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.jhepr.2023.100994_bib35","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2021.04.045","article-title":"Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens","volume":"75","author":"Shah","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib36","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/hep.30225","article-title":"Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r","volume":"69","author":"Fourati","year":"2019","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jhepr.2023.100994_bib37","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2020.05.029","article-title":"Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia","volume":"73","author":"Nguyen","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","article-title":"Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial","volume":"4","author":"Wei","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib39","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/hep.29837","article-title":"Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors","volume":"69","author":"Smith","year":"2019","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jhepr.2023.100994_bib40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","article-title":"Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial","volume":"4","author":"Wei","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib41","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir\u2013pibrentasvir for 8 or 12 Weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2023.100994_bib42","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2023.100994_bib43","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jhep.2017.06.035","article-title":"Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries","volume":"67","author":"da Silva Filipe","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib44","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jhep.2020.11.017","article-title":"Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy","volume":"74","author":"Dietz","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100994_bib45","first-page":"451","article-title":"Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir\/pibrentasvir, and ribavirin: a case report","volume":"58","author":"Bernhard","year":"2020","journal-title":"Z\u00a0Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100994_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa095","article-title":"Re-Treatment of hepatitis C infection after multiple failures of direct-acting antiviral therapy","volume":"7","author":"Fierer","year":"2020","journal-title":"Open Forum Infect Dis"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923003257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923003257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:32:18Z","timestamp":1762900338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555923003257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2589555923003257"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100994","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of voxilaprevir\/velpatasvir\/sofosbuvir in patients following DAA failure","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100994"}}